[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649631":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":39,"collaborators":41,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":72,"overallStatus":77,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mucosa Innovations, S.L.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Postmenopausal women with at least one symptom of GSM documented in their medical records.",null,"Postmenopausal women attended at the Department of Obstetrics and Gynecology of Hospital Universitario La Luz between January 2022 and April 2026, with at least one retrospectively documented symptom of GSM in their medical records and retrospectively documented use of the hormone-free vulvovaginal gel XCM INTIM for a minimum of 8 weeks.",[13],{"name":14,"affiliation":15,"role":16},"Manuel Albi-González, MD","Hospital Universitario La Luz Quirónsalud","PRINCIPAL_INVESTIGATOR",[18],{"name":19,"role":20,"phone":21,"phoneExt":10,"email":22},"Jorge Manuel Rodríguez-Vilaboa","CONTACT","+34629288597","jorge.vilaboa@mucosainnovations.com",[24],{"facility":15,"status":10,"city":25,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Madrid","28003","Spain","ES",{"type":30,"coordinates":31},"Point",[32,33],-3.70256,40.4165,{"lat":33,"lon":32},[36,38],{"name":14,"role":20,"phone":37,"phoneExt":10,"email":37},"malbi@quironsalud.es",{"name":14,"role":16,"phone":10,"phoneExt":10,"email":10},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[42,44],{"name":15,"class":43},"UNKNOWN",{"name":45,"class":43},"Clínica Vilaboa","100649631","retrospective-cohort-study-of-symptoms-and-quality-of-life-in-women-with-genitourinary-syndrome-of-menopause-100649631",false,"NCT07737782","Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.","Retrospective Observational Study in a Cohort of Postmenopausal Women With Genitourinary Syndrome of Menopause (GSM): Characterization of Symptoms and Impact on Quality of Life.","Inclusion Criteria:\n\nPatients included in this retrospective data evaluation must have met all of the following criteria:\n\n* Postmenopausal women (defined as at least 12 consecutive months of amenorrhea)\n* Present at least one symptom of GSM documented in the medical record\n* Evidence in the medical record that the patient had perceived the GSM symptom(s) as having an impact on her quality of life.\n* Documentation in the medical record that the patient had initiated treatment with XCM INTIM, together with follow-up clinical data including an assessment performed at least 8 weeks after treatment initiation.\n* Patients that had attended at the Department of Obstetrics and Gynecology of Hospital Universitario La Luz between January 2022 and April 2026, regardless of whether they had participated in another study during this period.\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following conditions were present:\n\n* Use of topical vulvovaginal hormonal products within 4 weeks prior to initiation of XCM INTIM treatment.\n* Use of systemic estrogen therapy within 8 weeks prior to initiation of XCM INTIM treatment.\n* Presence of relevant gynecological and\u002For urinary conditions that could have interfered with the assessment of symptoms attributed to GSM, including but not limited to active vulvovaginal and\u002For urinary tract infections, significant vulvar lesions, active gynecological malignancies, severe stress urinary incontinence (Sandvik score ≥ 8), pelvic organ prolapse stage III or higher (POP-Q), or any other condition considered by the investigator to be a significant confounding factor.\n* Previous radiotherapy involving the pelvic and\u002For genital region.\n* Previous laser and\u002For radiofrequency treatment in the pelvic region.\n* Medical records containing insufficient information for analysis of the primary study variables.","FEMALE","40 Years","75 Years",{"count":57,"type":58},100,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life. Moreover, based on data collected from medical records and\u002For patient-reported questionnaires, if available data enable it, it will be assessed whether treatment with the topical vulvovaginal gel XCM INTIM for a minimum of 8 weeks results in changes in symptom severity and in the impact of these symptoms across different quality-of-life domains.",[62,63,64,65,66,67,68,69,70,71],"Vulvar Atrophy","Vulvovaginal Signs and Symptoms","Genitourinary Syndrome of Menopause (GSM)","Quality of Life","Menopause Related Conditions","Dyspareunia","Urinary Incontinence, Urgency-frequency","Sexual Function","Women´s Health","Vaginal Dryness",[73,63,74,65,75,70,76],"Genitourinary Syndrome of Menopause","Patient Reported Outcome Measures","Day-to-Day Impact of Vaginal Ageing","Real World Data","NOT_YET_RECRUITING","2026-07-28",{"date":80,"type":81},"2026-07-30","ACTUAL",{"date":83,"type":58},"2026-07",{"date":85,"type":58},"2026-09",{"name":5,"class":6},1]